Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension-Reference-Cited by-同舟云学术

Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension

Published:2022-06-10 Issue:6 Volume:2022 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Clement Freiberg Josefine¹,von Spreckelsen Alexander¹,Kolko Miriam²,Azuara-Blanco Augusto³,Virgili Gianni⁴

Affiliation:

1. Department of Drug Design and Pharmacology; University of Copenhagen; Copenhagen Denmark

2. Department of Ophthalmology and Department of Drug Design and Pharmacology; Copenhagen University Hospital, University of Copenhagen; Copenhagen Denmark

3. Centre for Public Health; Queen's University Belfast; Belfast UK

4. Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA); University of Florence; Florence Italy

Publisher

Wiley

Subject

Pharmacology (medical)

Reference103 articles.

1. Study of netarsudil ophthalmic solution in Japanese/Japanese-American subjects with open-angle glaucoma or ocular hypertension clinicaltrials.gov/ct2/show/results/NCT03310580

2. Phase 2 randomized clinical study of netarsudil ophthalmic solution in Japanese patients with primary open-angle glaucoma or ocular hypertension;Araie;Advanced Therapies,2021

3. Efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan clinicaltrials.gov/ct2/show/NCT03844945

4. Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: pooled efficacy/safety analysis of phase 3 MERCURY-1 and -2;Asrani;Advanced Therapeutics,2020

5. Netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized phase 3 trial;Asrani;American Journal of Ophthalmology,2019

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm's Canal Constructs;Journal of Ocular Pharmacology and Therapeutics;2023-12-12

2. Pharmacologic and Natural Therapeutics in Glaucoma Management;Ocular Hypertension - New Advances [Working Title];2023-12-12

3. Glaucoma: now and beyond;The Lancet;2023-11

4. Rho-Kinase Inhibitors as Emerging Targets for Glaucoma Therapy;Ophthalmology and Therapy;2023-10-14

5. Rho-Kinase Inhibitors as Emerging Targets for Glaucoma Therapy;OPHTHALMOL THER;2023